4.2 Article

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 23, Issue 2, Pages 211-234

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2016.09.023

Keywords

Chronic graft-versus-host disease; Blood and marrow transplantation; lmmune mechanisms; Clinical manifestations

Funding

  1. Office of Rare Disease Research, National Center for Advancing Translational Sciences
  2. National Institute of Allergy and Infectious Diseases, Division of Allergy Immunology and Transplantation
  3. National Heart Lung and Blood Institute, Division of Blood Diseases and Resources
  4. Leukemia and Lymphoma Society of America
  5. Meredith A. Cowden Foundation
  6. National Institutes of Health's National Cancer Institute, Center for Cancer Research
  7. Intramural Research Program and Division of Cancer Treatment and Diagnosis
  8. Cancer Therapy Evaluation Program

Ask authors/readers for more resources

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: Summarize the current state of the science regarding pathogenic mechanisms of chronic GVHD and critical knowledge gaps. Develop Working hypotheses overriding concepts for chronic GVHD development. Define the usefulness of current preclinical models to test working hypotheses and ultimately discover and develop new therapeutic strategies. Identify shortcomings of preclinical models, and define criteria for the creation of additional models to address these limitations. This document is intended as a review of our understanding of chronic GVHD biology and therapies resulting from preclinical studies, and as a platform for developing innovative clinical strategies to prevent and treat chronic GVHD. Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available